Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 45Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Pleuropulmonary blastoma 1Patient Preference 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Multiple Myeloma 1Inflammatory Breast Neoplasms 1HER2 Positive Breast Cancer 1Genomic Instability 1Cholangiocarcinoma 1Breast Cancer Metastatic 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Doxorubicin 11Ifosfamide 9Radiotherapy 6Filgrastim 4pegfilgrastim 3Sorafenib 2Sirolimus 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Etoposide 2Chemotherapy, Adjuvant 2temsirolimus 1selinexor 1romidepsin 1ribociclib 1perifosine 1pazopanib 1lorvotuzumab mertansine 1liposomal doxorubicin 1indolepropanol phosphate 1exatecan 1cixutumumab 1brostallicin 1X-Rays 1Watchful Waiting 1Trabectedin 1Sunitinib 1Specimen Handling 1STA 9090 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neurofibrosarcoma × Ado-Trastuzumab Emtansine × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡